| Literature DB >> 31503548 |
Peng Tan1,2, Lian He2, Changsheng Xing1, Jingrong Mao1,3, Xiao Yu1, Motao Zhu1, Lixia Diao4, Leng Han5, Yubin Zhou2, M James You6, Helen Y Wang1, Rong-Fu Wang1,2,7.
Abstract
Beclin 1 (Becn1) is a key molecule in the autophagy pathway and has been implicated in cancer development. Due to the embryonic lethality of homozygous Becn1-deficient mice, the precise mechanisms and cell type-specific roles of Becn1 in regulating inflammation and cancer immunity remain elusive. Here, we report that myeloid-deficient Becn1 (Becn1ΔM) mice developed neutrophilia, were hypersusceptible to LPS-induced septic shock, and had a high risk of developing spontaneous precursor B cell (pre-B cell) lymphoma with elevated expression of immunosuppressive molecules programmed death ligand 1 (PD-L1) and IL-10. Becn1 deficiency resulted in the stabilization of MEKK3 and aberrant p38 activation in neutrophils, and mediated neutrophil-B cell interaction through Cxcl9/Cxcr3 chemotaxis. Neutrophil-B cell interplay further led to the activation of IL-21/STAT3/IRF1 and CD40L/ERK signaling and PD-L1 expression; therefore, it suppressed CD8+ T cell function. Ablation of p38 in Becn1ΔM mice prevented neutrophil inflammation and B cell tumorigenesis. Importantly, the low expression of Becn1 in human neutrophils was significantly correlated with the PD-L1 levels in pre-B acute lymphoblastic lymphoma (ALL) patients. Our findings have identified myeloid Becn1 as a key regulator of cancer immunity and therapeutic target for pre-B cell lymphomas.Entities:
Keywords: B cells; Cellular immune response; Immunology; Neutrophils; Oncology
Mesh:
Substances:
Year: 2019 PMID: 31503548 PMCID: PMC6877338 DOI: 10.1172/JCI127721
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808